We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc.
Zacks Investment Research on MSN
IRWD's Linzess wins FDA nod for expanded pediatric constipation use
Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess ...
Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...
The updated label now states that the treatment is contraindicated in patients less than 2 years of age due to the risk of serious dehydration. The Food and Drug Administration has approved revised ...
Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...
The FDA expanded its approval of linaclotide to include pediatric patients aged 2 to 5 years with functional ...
Tablets explicitly designed for weight reduction might be an excellent choice for those who want to get rid of excess weight in a hurry without having to make significant changes to their eating ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results